Abstract 4366509: Total Carotid Artery Calcium Score on Standard-of-care Oncologic Computed Tomography Scans Predicts Radiation-induced Carotid Artery Disease and its Sequelae in Patients with Oropharyngeal Cancer
Abstract
Introduction: Radiation therapy (RT) induced carotid artery disease (RICAD) is a significant contributor to morbidity and mortality of oropharyngeal cancer (OPC) survivors. Pre-existing carotid atherosclerosis is likely a risk factor for accelerated development of RICAD.Its evaluation prior to RT is not currently standard practice. This study aimed to utilize standard of care (SOC) oncologic pre-RT CT scans to quantify carotid calcific atherosclerosis and assess the role of carotid artery calcium score (CaACS) in predicting RICAD and its sequalae. Methods: Patients with OPC treated with RT at a tertiary center during 2016-19 were identified. SOC oncologic pre-RT CT of the neck with contrast was used to estimate CaACS utilizing the CT Cardiac package of SyngoVia (Siemens Healthcare). To separate calcified plaque from contrast, density threshold of 230 HU was used.Bilateral common and internal carotid arteries were evaluated to the C1 vertebra. Patients were split into three groups based on CaACS distribution:low (values ≤ median) as reference group,medium(values between median and 75th percentile),and high (values >75th percentile). Results: A total of 271 patients were included (mean age 61 ± 9.8, 88% male).Smoking was reported in 57%, hypertension (HTN) in 53%, dyslipidemia (DLD) in 43%, and diabetes mellitus (DM) in 14%,while 34% were on a statin prior to RT. Total median CaACS was 10.8 AU (IQR 0-140.6) with 46% having a score of 0. During a median follow up of 6.4 years (IQR 6.3-6.6), 41% developed new or worsened carotid atherosclerosis, 3.7% carotid artery stenosis >50%, 2.6% TIA or stroke, and 17% died without new or worsened carotid atherosclerosis. In a multivariate cause-specific Cox regression analysis, high CaACS was significantly associated with increased risk of the composite outcome of worsened carotid atherosclerosis, >50% stenosis, TIA or stroke (HR 2.18,95% CI[1.34-3.54]) compared to low CaACS. Hypertension was also associated with the composite outcome (2.26[1.49-3.41]) while no significant associations were noted with age, smoking, DLD, DM, or statin use. Fine-Gray analysis showed similar results. Conclusion: In our cohort of patients with OPC, high CaACS and history of HTN prior to RT, were significantly associated with development of RICAD. Quantification of carotid artery calcific atherosclerosis utilizing SOC oncologic CT imaging may assist with patient risk stratification, guide surveillance and potentially mitigate RICAD in OPC survivors.
Article Details
Authors (22)
Taher Kapadia
MD Anderson Cancer Center, Houston , Texas, United States
Dhawal Sanjay Bandrey
MD Anderson Cancer Center, Houston , Texas, United States
Bhumiben Patel
MD Anderson Cancer Center, Houston, Texas, United States
Patrik Joan Van Bergen Diaz
University of Barcelona, Barcelona, Spain
Jennifer Shen
MD Anderson Cancer Center, Pearland, Texas, United States
Gabrielle Mbagwu
MD Anderson Cancer Center, Houston, Texas, United States
Stephen Patin
MD Anderson Cancer Center, Houston , Texas, United States
Andres Hughes
MD Anderson Cancer Center, Houston, Texas, United States
Juhee Song
UT MD Anderson Cancer Center, Houston, Texas, United States
Ruitao Lin
MD Anderson Cancer Center, Houston, Texas, United States
Junichi Abe
University of Texas MD Anderson Can, Houston, Texas, United States
Nicolas Palaskas
UT MD Anderson Cancer Center, Houston, Texas, United States
Gregory Gladish
Amy Moreno
MD Anderson Cancer Center, Houston , Texas, United States
Mohamed Naser
Katherine Hutcheson
MD Anderson Cancer Center, Houston , Texas, United States
David Rosenthal
MD Anderson Cancer Center, Houston, Texas, United States
Elie Mouhayar
MD Anderson Cancer Center, Houston, Texas, United States
Anita Deswal
Clifton Fuller
Claire Viguet
Mcgovern Medical School, Houston, Texas, United States
Efstratios Koutroumpakis
UT MD Anderson Cancer Center, Houston, Texas, United States